Ovid therapeutics Inc (OVID)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.80+0.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OVID
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 77.3% |
| Our one-year growth estimate | diamond | -75.1% |
Growth built into the price is above our model estimate.
The price assumes 152.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OVID — CFO transition
Dated 2026-07-08
Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary — Jeffrey Rona: Mr. Rona mutually agreed to transition from his roles, resulting in a genuine departure.
Why it matters: Results from the Phase 1 study will show if OV4071 is safe and effective. This is key for future studies.
Supportive ifThe Phase 1 study shows that OV4071 is safe and tolerable.
Worry ifThe Phase 1 study shows safety issues or that it does not work well.
Why it matters: Updates on cash runway will show if Ovid can fund its work until 2028. This matters for investor confidence.
Watch forManagement says they have enough cash until 2029. This shows they are stable.
Also watch forManagement says the cash runway is shorter than they thought. This raises funding worries.
Why it matters: Earnings reports show how a company is doing financially. They can affect stock feelings.
Watch forThe earnings report shows revenue growth. It also has positive updates about operations.
Also watch forThe earnings report shows ongoing losses. It also has bad news about operations.
Why it matters: Funding is crucial for Ovid to support ongoing and future studies. It impacts their growth potential.
Supportive ifFunding has been secured for the clinical pipeline. This will last until 2H 2028.
Worry ifThere is no funding announcement. There are no signs of a funding shortfall.
Why it matters: Changes in cash burn rate will show how well Ovid manages expenses during clinical trials.
Worry ifOvid reports a decrease in cash burn rate compared to previous quarters.
Less concerning ifOvid's cash burn rate increases compared to previous quarters.
Why it matters: Starting clinical studies for OV4071 is key to Ovid's development plans. This will show if they can advance their pipeline.
Supportive ifOvid announces the start of clinical studies for OV4071 as planned in Q2 2026.
Worry ifOvid delays the initiation of clinical studies for OV4071 beyond Q2 2026.
Why it matters: Starting the Phase 2 study for OV329 is important. It helps treat resistant epilepsies.
Supportive ifOvid confirms the start of the Phase 2 study for OV329 in Q2 2026.
Worry ifOvid postpones the Phase 2 study for OV329 beyond Q2 2026.
Why it matters: Good results would show OV329's promise as a new epilepsy treatment. This could help Ovid's plans and boost investor trust.
Supportive ifOV329 shows strong seizure reduction in the Phase 2 study results by late 2027.
Worry ifOV329 does not show strong results in the Phase 2 study.
Why it matters: New studies for OV329 in pediatric indications could expand its market potential. This is important for growth.
Supportive ifStudies for OV329 are starting for children with conditions like TSC and IS.
Worry ifNo updates or delays in starting pediatric studies for OV329.
Why it matters: Expanding OV329 for children meets a big need in epilepsy treatments.
Supportive ifOvid shares news on OV329's progress for TSC seizures and infantile spasms.
Worry ifOvid does not provide updates or delays the programs for OV329 in children.
Why it matters: Results will confirm OV4071's potential for treating brain disorders. Positive data could boost investor confidence.
Supportive ifThe ketamine challenge study showed good results for OV4071's effects.
Worry ifThe ketamine challenge study showed bad results with no effects.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $692 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,478 loss on $10,000 · 34.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.